These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8995563)

  • 1. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
    Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
    Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
    Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
    Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
    Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
    Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
    Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
    J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P; Azen C; Lopez E; Platt LD; Karlan BY
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.
    Whitmore SE; Anhalt GJ; Provost TT; Zacur HA; Hamper UM; Helzlsouer KJ; Rosenshein NB
    Gynecol Oncol; 1997 May; 65(2):241-4. PubMed ID: 9159332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma.
    Kurihara T; Mizunuma H; Obara M; Andoh K; Ibuki Y; Nishimura T
    Gynecol Oncol; 1998 Jun; 69(3):192-6. PubMed ID: 9648586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms.
    Hall KL; Dewar MA; Perchalski J
    Prim Care; 1992 Sep; 19(3):607-20. PubMed ID: 1410066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ; Oram DH; Bast RC
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
    Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
    Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
    Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
    Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
    van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
    Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.